Open AccessS917 Use of Biologic Therapies With Different Mechanisms of Action (MOA) in the First-line (1L) Treatment of Crohn’s Disease (CD) in the U.S.
Author(s) -
Zhongwen Huang,
Yi Ba,
Pravin Kamble,
Song Wang
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000777200.39859.a0
Subject(s) - medicine , vedolizumab , ustekinumab , discontinuation , adalimumab , infliximab , crohn's disease , population , gastroenterology , disease , environmental health